NCT04745442View on ClinicalTrials.gov

Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 27, 2020

Primary Completion Date

December 20, 2020

Study Completion Date

January 15, 2021

Conditions
Covid19Severe Acute Respiratory SyndromeDistress Respiratory Syndrome
Interventions
DRUG

Antithrombin + best available treatment

The subject will be treated with Antithrombin (50 IU/Kg/12h) for 72 hours and the best available treatment for COVID-19.

DRUG

Best available treatment

The subject will be treated with the best available treatment for COVID-19.

Trial Locations (1)

14004

Hospital Universitario Reina Sofía, Córdoba

Sponsors
All Listed Sponsors
lead

Maimónides Biomedical Research Institute of Córdoba

OTHER